Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xcytrin in NSCLC brain metastases
NCT00054795Phase 3Completed
- Sponsor
- Pharmacyclics
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of motexafin gadolinium in brain metastases (2 arms), sponsored by Pharmacyclics. Primary endpoint: Time to Neurologic Progression. Status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT00054795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054795.